TheEdgeResearch
Home / Stocks / GRNA

GreenLight Biosciences Holdings (GRNA)

NASDAQ Healthcare Biotechnology
$0.30 ▼ -0.03%
Market Cap
$45.4M
Sector
Healthcare
Industry
Biotechnology
Beta
1.44
52-Wk Range
0.177-5.9
CEO
Andrey Juan Zarur
Country
US
Currency
USD

GreenLight Biosciences Holdings operates in the Biotechnology industry of the Healthcare sector, headquartered in Medford, MA, US. The stock last traded at $0.30, down 0.03% on the session, giving a market capitalisation of $45.4M. On trailing twelve-month figures it carries a trailing P/E of -0.24, a net margin of -2616.8%. Its beta of 1.44 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.24
Price / Sales
7.12
Price / Book
0.82
EV / EBITDA
-0.38
Gross margin
100.0%
Operating margin
-2567.7%
Net margin
-2616.8%
Return on equity
Debt / equity
1.67
Current ratio
2.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
280
IPO date
2022-02-03
Headquarters
Medford, MA, US
About GreenLight Biosciences Holdings

GreenLight Biosciences Holdings is a biotechnology firm focused on developing and commercializing ribonucleic acid (RNA) solutions. Its innovative products serve both the human health and agricultural industries. The company's human health portfolio includes mRNA vaccines and various therapeutic treatments, while its agricultural offerings feature RNA-based innovations designed to protect honeybees and defend crops. Established in 2008, GreenLight Biosciences Holdings is based in Medford, Massachusetts.

Comparable companies

GreenLight Biosciences Holdings is most often compared with the following Healthcare names:

ALVRBLUEERYPLIANYMGTAPSTIRENBRNTXSTSASYRE
More research on GRNA
GRNA technical analysis GRNA TheEdge Score Compare against peers
Open full interactive analysis & DCF →